Management of Kawasaki disease

Archives of Disease in Childhood

Volumn 99, Issue 1, 2014, Pages 74-83

  Eleftheriou, D ^a   Levin, M ^b   Shingadia, D ^a   Tulloh, R ^c   Klein, N J ^a   Brogan, P A ^a  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ACETYLSALICYLIC ACID; BCG VACCINE; C REACTIVE PROTEIN; CALCINEURIN INHIBITOR; CASPASE 3; CD40 ANTIGEN; CLOPIDOGREL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETANERCEPT; FC RECEPTOR IIA; HEPARIN; IMMUNOGLOBULIN; INFLIXIMAB; INOSITOL 1,4,5 TRISPHOSPHATE 3 KINASE C; INOSITOL TRISPHOSPHATE 3 KINASE; LOW AFFINITY IMMUNOGLOBULIN GAMMA FC REGION RECEPTOR II A; METHOTREXATE; METHYLPREDNISOLONE; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; PREDNISOLONE; SUPERANTIGEN; TOLL LIKE RECEPTOR AGONIST; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; VARICELLA ZOSTER VACCINE; WARFARIN;

ADD ON THERAPY; ASEPTIC MENINGITIS; BCG VACCINATION; BEHAVIOR; BONE NECROSIS; CLINICAL TRIAL (TOPIC); CONJUNCTIVITIS; CORONARY ARTERY ANEURYSM; CORONARY ARTERY DILATATION; CORONARY ARTERY OBSTRUCTION; CORONARY ARTERY THROMBOSIS; CORTICOSTEROID THERAPY; CROSS REACTION; DEVELOPED COUNTRY; DIAGNOSTIC TEST; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TREATMENT FAILURE; ECHOCARDIOGRAPHY; EPIDEMIOLOGICAL DATA; ERYTHROCYTE SEDIMENTATION RATE; ETHNIC GROUP; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEREDITY; HERPES ZOSTER; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOALBUMINEMIA; IMMUNIZATION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFLAMMATION; INFUSION RELATED REACTION; IRRITABILITY; LABORATORY TEST; LEUKOCYTE COUNT; LOW DRUG DOSE; LYMPHADENOPATHY; META ANALYSIS; MUCOCUTANEOUS LYMPH NODE SYNDROME; NONHUMAN; PATHOGENESIS; PLASMAPHERESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECOMMENDED DRUG DOSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RISK FACTOR; SCORING SYSTEM; SECONDARY INFECTION; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SYMPTOM; THROMBOCYTOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; UNITED KINGDOM;

INFECTIOUS DISEASES; RHEUMATOLOGY;

ADRENAL CORTEX HORMONES; CHILD, PRESCHOOL; CORONARY ANEURYSM; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MUCOCUTANEOUS LYMPH NODE SYNDROME;

EID: 84890557714     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/archdischild-2012-302841     Document Type: Review

References (87)

1. Harnden A, Alves B, Sheikh A. Rising incidence of Kawasaki disease in England: analysis of hospital admission data. BMJ 2002;324:1424-5.
2. Dillon MJ, Eleftheriou D, Brogan PA. Medium-size-vessel vasculitis. Pediatr Nephrol 2010;25:1641-52.
3. Gardner-Medwin JM, Dolezalova P, Cummins C, et al. Incidence of Henoch- Schonlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet 2002;360:1197-202.
4. Takahashi K, Oharaseki T, Yokouchi Y. Pathogenesis of Kawasaki disease. Clin Exp Immun 2011;164:20-2.
5. Yeung RS. Kawasaki disease: update on pathogenesis. Curr Opin Rheum 2010;22:551-60.
6. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and longterm management of Kawasaki disease. Circulation 2004;110:2747-71.
7. Burns JC, Shike H, Gordon JB, et al. Sequelae of Kawasaki disease in adolescents and young adults. J Am Coll Cardiol 1996;2:253-7.
8. Belay ED, Maddox RA, Holman RC, et al. Kawasaki syndrome and risk factors for coronary artery abnormalities: United States, 1994-2003. Pediatr Infect Dis 2006;25:245-9.
9. Brogan PA, Bose A, Burgner D, et al. Kawasaki disease: an evidence based approach to diagnosis, treatment, and proposals for future research. Arch Dis Child 2002;86:286-90.
10. Newburger JW, Sleeper LA, McCrindle BW, et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Eng J Med 2007;356:663-75.
11. Inoue Y, Okada Y, Shinohara M, et al. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome. J Pediatr 2006;149:336-41.
12. Burns JC, Mason WH, Hauger SB, et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr 2005;146:662-7.
13. Furusho K, Nakano H, Shinomiya K, et al. High-dose intravenous gammaglobulin for Kawasaki disease. The Lancet 1984;324:1055-8.
14. Kobayashi T, Saji T, Otani T, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet 2012;379:1613-20.
15. Nakamura Y, Yashiro M, Uehara R, et al. Epidemiologic features of Kawasaki disease in Japan: results from the nationwide survey in 2005-2006. J Epidem 2008;18:167-72.
16. MacNeil A, Holman R, Yorita K, et al . Evaluation of seasonal patterns of Kawasaki Syndrome-and rotavirus-associated hospitalizations in California and New York, 2000-2005. BMC Pediatrics 2009;9:65.
17. Holman RC, Curns AT, Belay ED, et al. Kawasaki syndrome hospitalizations in the United States; 1997 and 2000. Pediatrics 2003;112:495.
18. Rod X, Ballester J, Cayan D, et al. Association of Kawasaki disease with tropospheric wind patterns. Sci Rep 2011;1:152-6.
19. Esper F, Shapiro ED, Weibel C, et al. Association between a novel human coronavirus and Kawasaki disease. J Infect Dis 2005;191:499-502.
20. Nigro G, Krzysztofiak A, Porcaro MA, et al. Active or recent parvovirus B19 infection in children with Kawasaki disease. Lancet 1994;343:1260-1.
21. Chang LY, Chiang BL, Kao CL, et al. Lack of association between infection with a novel human coronavirus (HCoV), HCoV-NH, and Kawasaki disease in Taiwan. J Infect Dis 2006;193:283-6.
22. Meissner HC, Leung DY. Superantigens, conventional antigens and the etiology of Kawasaki syndrome. Pediatr Infect Dis 2000;19:91.
23. Abe J, Kotzin BL, Jujo K, et al. Selective expansion of T cells expressing T-cell receptor variable regions V beta 2 and V beta 8 in Kawasaki disease. PNAS 1992;89:4066-70.
24. Brogan PA, Shah V, Clarke LA, et al. T cell activation profiles in Kawasaki syndrome. Clin Experim Immun 2008;151:267-74.
25. Duong TT, Silverman ED, Bissessar MV, et al. Superantigenic activity is responsible for induction of coronary arteritis in mice: an animal model of Kawasaki disease. Intern Immunol 2003;15:79-89.
26. Rowley AH, Baker SC, Shulman ST, et al. Cytoplasmic inclusion bodies are detected by synthetic antibody in ciliated bronchial epithelium during acute Kawasaki disease. J Infect Dis 2005;192:1757-66.
27. Holman RC, Christensen KY, Belay ED, et al. Racial/Ethnic Differences in the Incidence of Kawasaki Syndrome among Children in Hawaiÿi. Hawaii Medical Journal 2010;69:194.
28. Fujita Y, Nakamura Y, Sakata K, et al. Kawasaki disease in families. Pediatrics 1989;84:666-9.
29. Weng KP, Hsieh KS, Hwang YT, et al. IL-10 polymorphisms are associated with coronary artery lesions in acute stage of Kawasaki disease. Circ Journ 2010;74:983.
30. Weng KP, Ho TY, Chiao YH, et al. Cytokine genetic polymorphisms and susceptibility to Kawasaki disease in Taiwanese children. Circ Journ 2010;74:2726.
31. Onouchi Y. Molecular genetics of Kawasaki disease. Pediatr Res 2009;65:46R-54R.
32. Onouchi Y. Genetics of kawasaki disease. Circul J 2012;76:1581.
33. Burgner D, Davila S, Breunis WB, et al. A genome-wide association study identifies novel and functionally related susceptibility Loci for Kawasaki disease. PLoS Genetics 2009;5:e1000319.
34. Onouchi Y, Ozaki K, Burns JC, et al. A genome-wide association study identifies three new risk loci for Kawasaki disease. Nat Genet 2012;44:517-21.
35. Lee YC, Kuo HC, Chang JS, et al. Two new susceptibility loci for Kawasaki disease identi fied through genome-wide association analysis. Nat Genet 2002;44:522-5.
36. Onouchi Y, Gunji T, Burns JC, et al. ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat Genet 2007;40:35-42.
37. Khor CC, Davila S, Breunis WB, et al. Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease. Nat Genet 2011;43:1241-6.
38. Khor CC, Davila S, Shimizu C, et al. Genome-wide linkage and association mapping identify susceptibility alleles in ABCC4 for Kawasaki disease. J Med Genet 2011;48:467-72.
39. Kim JJ, Hong YM, Sohn S, et al. A genome-wide association analysis reveals 1p31 and 2p13. 3 as susceptibility loci for Kawasaki disease. Hum Genet 2011;129:487-95.
40. Onouchi Y, Suzuki Y, Suzuki H, et al. ITPKC and CASP3 polymorphisms and risks for IVIG unresponsiveness and coronary artery lesion formation in Kawasaki disease. Pharmacogenomics J 2011;13:52-9.
41. Shimizu C, Jain S, Davila S, et al. Transforming Growth Factor-+| Signaling Pathway in Patients With Kawasaki DiseaseClinical Perspective. Circ Cardiov Gen 2011;4:16-25.
42. Diagnostic guidelines for Kawasaki disease. 5th edn. Japan Kawasaki Disease Research Committee Tokyo, 2002.
43. Amano S, Hazama F. Neural involvement in Kawasaki disease. Pathol Int 2008;30:365-73.
44. Sinha R, Balakumar T. BCG reactivation: a useful diagnostic tool even for incomplete Kawasaki disease. Arch Dis Child 2005;90:891.
45. Muise A, Tallett SE, Silverman ED. Are children with Kawasaki disease and prolonged fever at risk for macrophage activation syndrome? Pediatrics 2003;112:e495-7.
46. Mine K, Takaya J, Hasui M, et al. A case of Kawasaki disease associated with syndrome of inappropriate secretion of antidiuretic hormone. Acta Paediatrica 2004;93:1547-9.
47. Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 2006;113:2606-12.
48. Watanabe T, Abe Y, Sato S, et al. Sterile pyuria in patients with Kawasaki disease originates from both the urethra and the kidney. Ped Neph 2007;22:987-91.
49. Egami K, Muta H, Ishii M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Ped 2006;149:237-40.
50. Sano T, Kurotobi S, Matsuzaki K, et al. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur Journ Ped 2007;166:131-7.
51. Sleeper LA, Minich LL, McCrindle BM, et al. Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. J Pediatr 2011;158:831-5.
52. Tremoulet AH, Best BM, Song S, et al. Resistance to intravenous immunoglobulin in children with Kawasaki disease. J Pediatr 2008;153:117-21.
53. Durongpisitkul K, Gururaj VJ, Park JM, et al. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics 1995;96:1057-61.
54. Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991;324:1633-9.
55. Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr 1997;131:888-93.
56. Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics 1979;63:175-9.
57. Furukawa T, Kishiro M, Akimoto K, et al. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease. Arch Dis Child 2008;93:142-6.
58. Okada K, Hara J, Maki I, et al. Pulse methylprednisolone with gammaglobulin as an initial treatment for acute Kawasaki disease. Eur Jour Pediatr 2009;168:181-5.
59. Sundel RP, Baker AL, Fulton DR, et al. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial. J Pediatr 2003;142:611-6.
60. Chen S, Dong Y, Yin Y, et al. Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis. Heart 2013;99:76-82.
61. Latino GA, Manlhiot C, Yeung RS, et al. Macrophage activation syndrome in the acute phase of Kawasaki disease. J Ped Hem/Onc 2010;32:527-31.
62. Lega JC, Bozio A, Cimaz R, et al. Extracoronary echocardiographic findings as predictors of coronary artery lesions in the initial phase of Kawasaki disease. Arch Dis Child 2013;98:97-102.
63. Lau AC, Duong TT, Ito S, et al. Matrix metalloproteinase 9 activity leads to elastin breakdown in an animal model of Kawasaki disease. Arthritis Rheum 2008;58:854-63.
64. Weiss JE, Eberhard BA, Chowdhury D, et al. In fliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol 2004;31:808-10.
65. Oishi T, Fujieda M, Shiraishi T, et al. Infliximab treatment for refractory Kawasaki disease with coronary artery aneurysm. Circ J 2008;72:850.
66. Brogan RJ, Eleftheriou D, Gnanapragasam J, et al. Infliximab for the treatment of intravenous immunoglobulin resistant Kawasaki disease complicated by coronary artery aneurysms: a case report. Pediatr Rheumatol Online J 2009;7:3.
67. Matsubara T, Furukawa S, Yabuta K. Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-in Kawasaki disease involved coronary-artery lesions. Clin Immunol Immunopathol 1990;56:29-36.
68. Burns JC, Best BM, Mejias A, et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr 2008;153:833-8.
69. Son MB, Gauvreau K, Burns JC, et al. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study. J Pediatr 2011;158:644-9.
70. Choueiter NF, Olson AK, Shen DD, et al. Prospective open-label trial of etanercept as adjunctive therapy for Kawasaki disease. J Pediatr 2010;157:960-6.
71. Tremoulet AH, Pancoast P, Franco A, et al. Calcineurin Inhibitor Treatment of Intravenous Immunoglobulin - Resistant Kawasaki Disease. J Pediatr 2012;161:506-12.
72. Suzuki H, Terai M, Hamada H, et al. Cyclosporin A treatment for Kawasaki disease refractory to initial and additional intravenous immunoglobulin. Pediatr Infect Dis J 2011;30:871-6.
73. Akman-Demir G, Ayranci O, Kurtuncu M, et al. Cyclosporine for Behcet's uveitis: Is it associated with an increased risk of neurological involvement? Clin & Experim Rheum 2008;26:84.
74. Sugahara Y, Ishii M, Muta H, et al. Warfarin therapy for giant aneurysm prevents myocardial infarction in Kawasaki disease. Ped Cardiol 2008;29:398-401.
75. John Looney R, Huggins J. Use of intravenous immunoglobulin G (IVIG). Best Pract & Res Clin Haem 2006;19:3-25.
76. Dhillon R, Newton L, Rudd PT, et al. Management of Kawasaki disease in the British Isles. Arch Dis Child 1993;69:631-8.
77. Sasaguri Y, Kato H. Regression of aneurysms in Kawasaki disease: a pathological study. J Pediatr 1982;100:225-31.
78. Takahashi M, Mason W, Lewis AB. Regression of coronary aneurysms in patients with Kawasaki syndrome. Circulation 1987;75:387-94.
79. Kato H, Sugimura T, Akagi T, et al. Long-term consequences of Kawasaki disease: a 10-to 21-year follow-up study of 594 patients. Circulation 1996;94:1379-85.
80. Nakamura Y, Aso E, Yashiro M, et al. Mortality among persons with a history of kawasaki disease in Japan: mortality among males with cardiac sequelae is significantly higher than that of the general population. Circ J 2008;72:134.
81. Suda K, Iemura M, Nishiono H, et al. Long-term prognosis of patients with Kawasaki disease complicated by giant coronary aneurysms clinical perspective. Circulation 2011;123:1836-42.
82. Daniels LB, Tjajadi MS, Walford HH, et al. Prevalence of Kawasaki disease in young adults with suspected myocardial ischemia clinical perspective. Circulation 2012;125:2447-53.
83. Daniels LB, Gordon JB, Burns JC. Kawasaki disease: late cardiovascular sequelae. Curr Opin in Cardiol 2012;27:572-7.
84. Akagi T. Catheter interventions for Kawasaki disease: current concepts and future directions. Kor Circul Journ 2011;41:53-7.
85. Tsuda E, Fujita H, Yagihara T, et al. Competition between native flow and graft flow after coronary artery bypass grafting. Impact on indications for coronary artery bypass grafting for localized stenosis with giant aneurysms due to Kawasaki disease. Ped Cardiol 2008;29:266-70.
86. Tsuda E, Kitamura S, Kimura K, et al. Long-term patency of internal thoracic artery grafts for coronary artery stenosis due to Kawasaki disease: comparison of early with recent results in small children. Am Heart Journ 2007;153:995-1000.
87. Kahn AM, Budoff MJ, Daniels LB, et al. Calcium scoring in patients with a history of Kawasaki disease. JACC: Cardiov Imag 2012;5:264-72.